Metrics as of 10/17/2026, 08:55 AM (Berlin time), refresh in progress.
ImageneBio Stock
ImageneBio Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kristin Yarema
- Employees
- 18
- Market cap
- $46 M
- IPO
- 27/02/1998
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor…
ImageneBio stock: price history
1D
+0.2%
1W
-4.7%
1M
-18.1%
6M
-31.5%
YTD
-41.4%
1Y
-46.8%
2Y
-80.4%
5Y
-97.2%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~101% stronger price swings than usual
Ask the agents about ImageneBio
Analyst assessment of ImageneBio
PRICE TARGET LOW
US$1.33
CONSENSUS
US$1.33
MEDIAN
US$1.33
PRICE TARGET HIGH
US$1.33
0
STRONG BUY
4
BUY
0
HOLD
1
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/05/2026
ImageneBio stock metrics
P/E
-0.78
P/B
0.46
EV/EBITDA
0.89
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
63.9%
FLOAT SHARES
7,256,889
AVG. DAILY VOLUME (30D)
16,368
Insider transactions (SEC)
Grant-Huerta Yanina
Grant-Huerta Yanina
Yarema Kristin
Yarema Kristin
Yarema Kristin
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about ImageneBio stock
What does ImageneBio do?
ImageneBio Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kristin Yarema, the company employs around 18 people.
The IPO was on 27/02/1998; the stock trades on NASDAQ under the ticker IMA.
What do analysts say about ImageneBio stock?
5 analysts rate the stock, the consensus is Buy (as of 11/05/2026).
The average price target is US$1.33, ranging from US$1.33 to US$1.33, with a median of US$1.33.
This is an external assessment, not a statement by Market Jury.
When does ImageneBio report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 101% stronger than usual.
Does ImageneBio pay a dividend?
No, ImageneBio currently does not pay a dividend.
Which stocks are comparable to ImageneBio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ImageneBio stock analyzed?
Clicking "Analyze stock" lets five strategies assess ImageneBio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.